

Best-Value Biological Medicine Evaluation Process: Denosumab 60 mg

The HSE-Medicines Management Programme (MMP) is undertaking a best-value biological (BVB) medicine evaluation process for medicinal products containing denosumab 60 mg. The submission phase of this process commences on Wednesday 29 April 2026.

The BVB medicine evaluation process will be carried out in accordance with the *Processes for the Assessment and Selection of Best-Value Biological (BVB) Medicines / Best-Value Medicines (BVM)*, as outlined in schedule 2 of the Framework Agreements on the Supply and Pricing of Medicines (FASPM) 2026-2029. The criteria that the MMP will consider in identifying BVB medicines for denosumab 60 mg are outlined in section 15 of schedule 2 of FASPM 2026-2029.

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 5pm on Tuesday 28 July 2026.